Despite the more than $50 billion that U.S. pharmaceutical companies have spent every year since the mid-2000s to discover new medications, drugmakers have barely improved on old standbys developed decades ago, a study from Columbia University and the University of Pennsylvania found. Aaron Kesselheim, HMS assistant professor of medicine at Brigham and Women’s Hospital and research associate in Health Policy and Management at Harvard School of Public Heath is quoted.
